JP2013504603A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013504603A5 JP2013504603A5 JP2012529062A JP2012529062A JP2013504603A5 JP 2013504603 A5 JP2013504603 A5 JP 2013504603A5 JP 2012529062 A JP2012529062 A JP 2012529062A JP 2012529062 A JP2012529062 A JP 2012529062A JP 2013504603 A5 JP2013504603 A5 JP 2013504603A5
- Authority
- JP
- Japan
- Prior art keywords
- csf
- antibody
- cns
- use according
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24250309P | 2009-09-15 | 2009-09-15 | |
| US61/242,503 | 2009-09-15 | ||
| PCT/AU2010/001191 WO2011032204A1 (en) | 2009-09-15 | 2010-09-14 | Treatment of neurological conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015109380A Division JP2015187135A (ja) | 2009-09-15 | 2015-05-29 | 神経疾患の処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013504603A JP2013504603A (ja) | 2013-02-07 |
| JP2013504603A5 true JP2013504603A5 (enExample) | 2013-10-10 |
| JP5785550B2 JP5785550B2 (ja) | 2015-09-30 |
Family
ID=43757935
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529062A Expired - Fee Related JP5785550B2 (ja) | 2009-09-15 | 2010-09-14 | 神経疾患の処置方法 |
| JP2015109380A Pending JP2015187135A (ja) | 2009-09-15 | 2015-05-29 | 神経疾患の処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015109380A Pending JP2015187135A (ja) | 2009-09-15 | 2015-05-29 | 神経疾患の処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9364534B2 (enExample) |
| EP (1) | EP2477656B1 (enExample) |
| JP (2) | JP5785550B2 (enExample) |
| KR (1) | KR101750426B1 (enExample) |
| CN (1) | CN102630167B (enExample) |
| AU (1) | AU2010295223B2 (enExample) |
| CA (1) | CA2773552C (enExample) |
| DK (1) | DK2477656T3 (enExample) |
| ES (1) | ES2623802T3 (enExample) |
| PL (1) | PL2477656T3 (enExample) |
| WO (1) | WO2011032204A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110117092A1 (en) * | 2009-10-20 | 2011-05-19 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting g-csfr |
| RU2605595C2 (ru) | 2011-06-13 | 2016-12-20 | СиЭсЭл Лимитид | Антитела против g-csfr и их применение |
| GB201401465D0 (en) * | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
| US20210179721A1 (en) | 2017-11-29 | 2021-06-17 | Csl Limited | Method of treating or preventing ischemia-reperfusion injury |
| US12281160B2 (en) | 2018-03-23 | 2025-04-22 | Csl Limited | Method of treating asthma |
| WO2019226550A1 (en) * | 2018-05-21 | 2019-11-28 | CHS Pharma Inc. | Granulocyte colony-stimulating factor (gcsf) gene therapy for treating neurological diseases |
| BR112021010920A2 (pt) * | 2018-12-04 | 2021-08-31 | CSL Innovation Pty Ltd | Método de tratamento de condições neutrofílicas |
| EP4739706A1 (en) | 2023-07-05 | 2026-05-13 | CSL Innovation Pty Ltd | Methods of treating or preventing a complication of sickle cell disease |
| WO2025217678A1 (en) * | 2024-04-15 | 2025-10-23 | CSL Innovation Pty Ltd | Methods of treating or delaying progression or hindering development of a neutrophil-associated condition |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IE66494B1 (en) | 1989-09-26 | 1996-01-10 | Immunex Corp | Granulocyte-colony stimulating factor receptors |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| WO1997042224A1 (en) * | 1996-05-07 | 1997-11-13 | Millennium Biotherapeutics, Inc. | Neurotactin and uses therefor |
| EP1261337B1 (en) * | 2000-02-28 | 2008-09-10 | The University Of British Columbia | Topoisomerase inhibitors for treatment of surgical adhesions |
| US7108852B2 (en) * | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| WO2002078643A2 (en) * | 2001-03-30 | 2002-10-10 | Philadelphia Health And Education Corporation | Immunomodulation and effect on cell processes relating to serotonin family receptors |
| US20060093604A1 (en) * | 2002-08-23 | 2006-05-04 | The Walter And Eliza Hall Institute Of Medical Research | Method of treatment and prophylaxis |
| AU2004244626A1 (en) * | 2003-05-23 | 2004-12-09 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GITR ligand and GITR ligand-related molecules and antibodies and uses thereof |
| WO2005121174A2 (en) * | 2004-06-04 | 2005-12-22 | Five Prime Therapeutics, Inc. | Novel g-csf polypeptides, polynucleotides, modulators thereof, and methods of use |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CA2654894A1 (en) | 2006-07-06 | 2008-10-01 | Laboratoires Serono S.A. | Csf3r polypeptides and uses thereof |
| AU2007283463B2 (en) | 2006-08-11 | 2012-04-26 | Csl Limited | Treatment of pulmonary disease conditions |
| WO2008125903A2 (en) * | 2006-12-12 | 2008-10-23 | Chaim Sheba Medical Center | Method of inhibiting an undesired immune response |
-
2010
- 2010-09-14 EP EP10816462.5A patent/EP2477656B1/en active Active
- 2010-09-14 AU AU2010295223A patent/AU2010295223B2/en not_active Ceased
- 2010-09-14 CA CA2773552A patent/CA2773552C/en active Active
- 2010-09-14 DK DK10816462.5T patent/DK2477656T3/en active
- 2010-09-14 US US12/881,293 patent/US9364534B2/en active Active
- 2010-09-14 KR KR1020127008842A patent/KR101750426B1/ko not_active Expired - Fee Related
- 2010-09-14 ES ES10816462.5T patent/ES2623802T3/es active Active
- 2010-09-14 CN CN201080048357.7A patent/CN102630167B/zh not_active Expired - Fee Related
- 2010-09-14 WO PCT/AU2010/001191 patent/WO2011032204A1/en not_active Ceased
- 2010-09-14 JP JP2012529062A patent/JP5785550B2/ja not_active Expired - Fee Related
- 2010-09-14 PL PL10816462T patent/PL2477656T3/pl unknown
-
2014
- 2014-03-24 US US14/223,315 patent/US9352038B2/en active Active
-
2015
- 2015-05-29 JP JP2015109380A patent/JP2015187135A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | CXCL12-CXCR4/CXCR7 axis in cancer: from mechanisms to clinical applications | |
| JP7395483B2 (ja) | ｍＲＮＡの細胞内送達のためのペプチドおよびナノ粒子 | |
| US10479997B2 (en) | Compositions and methods for diagnosis and treatment of prostate cancer | |
| JP2021525248A5 (enExample) | ||
| JP2022527108A5 (enExample) | ||
| JP2021529780A (ja) | Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法 | |
| EP3191592A1 (en) | Inhibition of prmt5 to treat mtap-deficiency-related diseases | |
| US20140004156A1 (en) | Biological inhibitors of ror1 capable of inducing cell death | |
| JP2014076062A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| US20250295809A1 (en) | Compositions and methods for the treatment of her2 positive cancer | |
| TWI858005B (zh) | 肝毒性之治療 | |
| JP2006525796A5 (enExample) | ||
| JP2012521217A5 (enExample) | ||
| CN119343142A (zh) | 治疗具有与血细胞分化相关的临床显著体征和症状的受试者的方法 | |
| TWI500629B (zh) | 介白素－６抗體及其用途 | |
| JP2015522264A5 (enExample) | ||
| JP2010500291A5 (enExample) | ||
| AU2019236656A1 (en) | Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma | |
| JP2021514003A5 (enExample) | ||
| JP2020511493A (ja) | セマフォリン−４ｄ抗体とエピジェネティック調節剤の組み合わせを用いたがんの処置方法 | |
| JP2021520393A5 (enExample) | ||
| AU2018314236A1 (en) | RNA aptamers against transferrin receptor (TfR) | |
| TW201836610A (zh) | Wnt抑制劑與抗-pd-1抗體分子組合之給藥方案 | |
| JP2023520103A (ja) | ＦｏｘＰ３発現を阻害する修飾されたアンチセンスオリゴヌクレオチド |